Russia’s N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology that created Sputnik V vaccine against Covid-19 proceeded to the development of the anti-coronavirus drug on the basis of monoclonal antibodies as Interfax reported citing the Center’s Director Alexander Gintsburg.
“We can create these (monoclonal) antibodies brilliantly, during nine months we are persuading the Health Ministry to allocate some money. Two or three weeks ago, when Trump recovered, they started to allocate money,” Gintsburg noted.
According to his predictions, the drug will be created during three-four months; then, it will pass the clinical trials during seven or eight months.
The scientist hopes that in a year, the drug with monoclonal antibodies will be registered in a year.
Gintsburg reminded that his center has already created a similar drug for the treatment of the Ebola.
On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.
The vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and the Russian Binnopharm Company. According to Murashko, currently, they finalize technical regulations for scaling production at the number of Russian companies.
Earlier, the Health Ministry of Russia oublicly released the first batch of Sputnik V vaccine against the coronavirus.
Meanwhile, Russian leader Vladimir Putin does not rule out that his country could provide supplies of Sputnik-V vaccine to Ukraine. He said so during his meeting with Viktor Medvedchuk, the Chairman of Political Council of Opposition Platform-For Life party.
On November 11, it was reported that the effectiveness of the Russian Sputnik V vaccine against coronavirus made 92% on the results of the interim analysis of the data of the third phase of the clinical trial.